- Title: Sexual dysfunction among Nigerian women living with HIV infection 1
- Oliver Ezechi^{1,2}, Folahanmi Akinsolu^{1,2}, Tititola Gbajabiamila¹, Ifeoma Idigbe^{1&}, Paschal 2
- Ezeobi^{1,2}, Adesola Musa^{1,2&}, Agatha Wapmuk¹ 3
- 4
- 5 ¹Center for Reproduction and Population Health Studies, Department of Clinical Sciences, Nigerian
- 6 Institute of Medical Research, Yaba, Lagos State, Nigeria
- 7 ²Department of Public Health, Faculty of Basic Medical and Health Sciences, Lead City University,
- Ibadan, Oyo State, Nigeria 8
- 9 *Corresponding author
- E-mail: folahanmi.tomiwa@gmail.com: Akinsolu.folahanmi@lcu.edu.ng 10
- 11
- [□]These authors contributed equally to this work. 12
- [&]These authors also contributed equally to this work. 13
- 14
- 15
- 16

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

perpetuity. It is made available under a CC-BY 4.0 International license .

17 ABSTRACT

18 Introduction

- 19 Sexual dysfunction in women with HIV is a necessary but understudied aspect of HIV complications in women
- 20 living with HIV. This study reports the prevalence, pattern, and risk factors for sexual dysfunction in women
- 21 living with HIV in southwest Nigeria.

22 Methods

- 23 A validated Female Sexual Function Index was used to determine sexual dysfunction in a cross-sectional study
- 24 design involving 2926 adult women living with HIV in a large, publicly funded tertiary HIV treatment centre
- 25 in Lagos, Nigeria. A score of less than 26.5 indicated sexual dysfunction. Multivariate logistic regression
- 26 analysis was performed to identify risk factors for sexual dysfunction. P < 0.05 was considered statistically
- 27 significant at a 95% confidence interval (CI).

28 **Results**

- 29 The prevalence of sexual dysfunction was 71.4%. The types of dysfunctions detected included disorder of
- desire (76.8%), sexual arousal (66.0%), orgasm (50.0%), pain (47.2%), lubrication (47.2%), and satisfaction (38.8%). Multivariate analysis showed that menopause (aOR: 2.0; 1.4 4.1), PHQ score of 10 and above
- (aOR: 2.3; 1.7 3.2), co-morbid medical conditions (aOR: 1.8; 1.4 2.7), use of protease inhibitor-based
- 33 antiretroviral therapy (aOR: 1.3; 1.2 2.1) and non-disclosure of HIV status (aOR: 0.7; 0.6-0.8) were factors
- 34 associated with sexual dysfunction.

35 Conclusions

- 36 Sexual dysfunction is common among Nigerian women living with HIV. Menopause, use of protease 37 inhibitor-based regimens, PHQ score of at least 10, co-morbid medical condition, and non-disclosure of HIV 38 status were associated with sexual dysfunction. National HIV programmes, in addition to incorporating 39 screening and management of sexual dysfunction in the guidelines, should sensitise and train health workers 40 on the detection and treatment of sexual dysfunction.
- 41
- 42 Abstract word count: 257
- 43
- Keywords: Sexual dysfunction, female sexual dysfunction, Female Sexual Function Index, human
 immunodeficiency virus, antiretroviral therapy, protease inhibitor, Nigeria
- 46

medRxiv preprint doi: https://doi.org/10.1101/2023.09.19.23295767; this version posted September 21, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY 4.0 International license .

Introduction 48

- The introduction and increased access to antiretroviral therapy have changed human immunodeficiency virus 49
- (HIV) infection, a disease once considered a death sentence, to a chronic, manageable health condition. The 50 widespread availability and use of potent combination antiretroviral therapy have dramatically reduced the
- 51
- morbidity and mortality of HIV infection globally and in sub-Saharan Africa.⁴ 52

The marked improvement in the clinical outcome of HIV infection has prompted a paradigm shift in the 53 measure of HIV treatment success from mortality to quality of life.⁵ Quality of life is a multidimensional 54 construct defined as a subjective evaluation of one's functioning and well-being. It is affected not only by 55 individual lifestyle but also by social norms, cultural practices, and belief systems, so it varies among regions 56 and population groups.^{6,7} 57

- Numerous studies in sub-Saharan Africa have examined the health-related quality of life in HIV-infected 58 59 persons, with most studies emphasizing the physical, mental, and social aspects of quality of life while leaving out the sexual function component.⁷⁻²¹ The few studies that addressed some aspect of sexual functioning were 60 either limited by sample size or did not use a globally accepted and validated tool, such as Female Sexual 61 Function Index questionnaire, in conducting their study.¹⁹⁻²¹ Few studies focused on sexual dysfunction among 62
- HIV-positive women, even though a high prevalence of sexual dysfunction in persons living with HIV/AIDS 63
- has been reported .22-24 64
- There are many reasons to expect an increase in sexual dysfunction in persons living with HIV infections, 65 with psychological, endocrine, and neurologic factors being the most important. ²⁵⁻²⁷ However, proving a link 66 67 between these factors and sexual dysfunction is difficult, as many of the conditions commonly seen within the HIV context, such as depression, peripheral neuropathy, and hypogonadism, are associated with sexual 68 dysfunction in other settings also.^{25,26} Furthermore, establishing associations with drugs or classes of drugs is 69 difficult, as these agents often are used in combinations, and some of the drug-related toxicities persist even 70 after replacement with another drug, leading to wrong attribution.^{25,28,29} 71
- Whereas several studies have evaluated sexual dysfunction in HIV-positive men,³⁰ but few studies have 72 examined the sexual function of women living with HIV/AIDS.²⁵ In Nigeria, despite its high HIV burden, an 73 74 extensive literature search has revealed only three studies reporting on sexual dysfunction among HIV-positive women, ²²⁻²⁴ despite several studies on sexual dysfunction among women with chronic diseases, pregnancy, 75 76 infertility, diabetes mellitus, or hypertension.³¹⁻³⁶ This study was conducted to determine the prevalence, pattern, and risk factors of sexual dysfunction among HIV-positive women in Lagos, Southwest Nigeria. 77
- 78
- 79

Methods 80

Study setting, design, sample size, and sampling 81

This cross-sectional study was conducted between January 2019 and December 2020 at a large publicly funded 82 tertiary comprehensive HIV treatment centre in a cosmopolitan city in southwestern Nigeria. The centre has 83 cumulatively enrolled over 25,000 HIV-positive clients, 65% of whom are women. To participate in the study, 84 the women had to be older than 18 years and proven HIV-positive for more than six months. The minimal 85 sample size for the study was calculated with Raosoft online sample size calculator (86 http://www.raosoft.com/samplesize.html),³⁸ with a 99% CI, 2.5% margin of error, and assumed prevalence of 87 sexual dysfunction among HIV positive to be 61.0%.²¹ A total sample size of 2916 HIV-positive women was 88 required, assuming a 30% non-response rate. A total of 3205 respondents randomly selected from the clinic 89 attendance register were recruited for the study. 90

HIV-positive women attending the treatment centre were approached for the interview after selection from 91 the lists of attendees, using a proportionate stratified sampling method. This method enabled the generalization 92 93 of the study's findings to the women in the clinic. Each clinic's two-patient categories, drug refill; and 3-6 94 monthly physician consults, were considered a homogenous population. These two categories were often in the ratio of 2:1 at each of the three clinic days a week. The daily list of clinic attendees was categorized into 95 the two groups above, each serving as a frame. Respondents were then selected from the frames by simple 96 random sampling, using the ratio of 2:1. Those who accepted to participate and signed an informed consent 97 form were recruited. 98

99

Study tools, data collection, and statistical analysis 100

A self-administered structured data collection form consisting of three sections. (A) Demographic 101 characteristics, (B) Patient Depression Question (PHQ), and (C) Female Sexual Function Index, were used to 102 collect data for the study. Low-literate respondents were assisted in completing the forms by trained research 103 assistants. The respondents' hospital numbers were written on each form to enable linkage to respondents' 104 medical records. The demographic section of the form captured respondents' socioeconomic characteristics, 105 medical and reproductive history, current and previous antiretroviral treatment, and recent laboratory results 106 (CD4 cell count and viral load). The second section was the PHQ-9,^{39,40,} a 9-item self-report questionnaire in 107 which participants rated their feelings during the previous two weeks. Each question is scored 0 to 3 (0 = not108 at all, 1 = several days, 2 = more than half the days, and 3 = nearly every day), resulting in a 0 to 27. The nine 109 items reflect the DSM-IV criteria for major depressive disorders. For this study, a score of 10 and above was 110 considered depression. The last section is the Female Sexual Function Index (FSFI)^{41,42}, a 19-item self-report 111 instrument that scores six domains of sexual function in women in the previous four weeks. These domains 112 include desire (two items, questions 1–2), arousal (four items, questions 3–6), lubrication (four items, 113 questions 7–10), orgasm (three items, questions 11–13), satisfaction (three items, questions 14–16), and pain 114 (three items, questions 17–19). The total FSFI score was determined by the sum of the six domains, with the 115 minimum and maximum scores possibly varying from 2.0 to 36.0. A score greater than 26.5 denoted a low 116 level of sexual dysfunction, and a score of 26.5 or less indicated sexual dysfunction. Likewise, scores on 117 desire, arousal, lubrication, orgasm, satisfaction, and pain, which are ≤ 3.6 (score range, 1.2–6), ≤ 3.9 (score 118 range, 0-6), ≤ 3.6 (score range, 0-6), ≤ 3.6 (score range, 0-6), ≤ 3.6 (score range, 0-6) and ≤ 4.4 (score range, 0-6) 119 0-6), respectively; all indicate sexual dysfunction related to subdimensions. ^{32,41-43} The FSFI has been 120 validated on a clinically diagnosed sample of women with female sexual disorders.⁴⁴ In our setting, ⁴³ however, 121 because the study was in a specific population, the validity and reliability in the study population were 122 123 confirmed with 100 HIV-positive women. A Cronbach's alpha score of 0.85 was obtained, indicating good reliability. 124

The study results were presented as means and percentages. The total FSFI scores were categorized into 125 dichotomous variables (normal sexual function and sexual dysfunction) using a cut-off point of 26.5.42,43 126

- Frequency distributions were generated, and univariate analysis using relevant statistics was performed to 127 identify factors associated with sexual dysfunction. Multivariate logistic regression was used to identify 128 independent risk factors for sexual dysfunction while controlling for potential confounders, including the 129 severity of HIV disease measured by CD4 count and HIV viral load, time since HIV diagnosis, duration of 130 antiretroviral drug use. PHO-9 score of > 10. co-morbid state, education, employment status, marital status, 131 age, and menopausal state. Variables were entered into the model if their P value on univariate analysis was 132 < 0.25 or less. The variable with the strongest association in the univariate model was estimated first. followed 133 by others in descending order. In the analysis, the comparison group consisted of those with an FSFI score of 134 > 26.5 (no sexual dysfunction). P < 0.05 was considered statistically significant. Odds Ratios (OR) and 95% 135 Confidence Intervals (CI) for the OR were also calculated. All analyses were performed with SPSS statistical 136 software package version 23.0 for Windows, SPSS Inc., Chicago, IL, USA. 137
- 138

Ethical considerations 139

Ethical approval for the study was obtained from the Institutional Review Board of the Nigerian Institute of 140 Medical Research, Lagos, Nigeria. Written informed consent was obtained from participants after the study 141 objectives and methods were explained to the participants. The participants were assured of the confidentiality 142 and anonymity of their data during and after the study. The women who declined to consent to participate in 143 the study were provided their routine care but excluded from participation in the study. 144

145

Results 147

- 3205 HIV-positive women were approached to participate in the study, of which 3009 (93.9%) accepted and 148 149 were given the study forms or interviewed by research assistants. The study forms 2926 (91.3%) women in a stable monogamous and heterosexual relationship were completed and retrieved. 150
- 151

Sociodemographic and HIV-related characteristics of the respondents 152

The sociodemographic characteristics of the HIV-positive women in the study are shown in Table 1. Most of 153 the women were less than 35 years of age (68.5%), married (53.1%), Christian (73.2%), working (59.5%), 154 and from one of the three major Nigerian ethnic groups (75.8%). 78.5% had completed at least a secondary 155 education. Four hundred and thirty-two (14.8%) HIV-positive women were postmenopausal. 156

- HIV-related characteristics of the respondents are shown in Table 2, and the time elapsed since HIV diagnosis 157 ranged from 6 to 204 months, with a median of 102 ± 41 months. In most respondents (56.5%), HIV diagnosis 158 had been made within 120 months. Most of the women had CD4 cell counts above 200 cells/mm³ (73.6%). 159 not detectable HIV viral load (62.3%), HIV positive partners (56.5%) and had disclosed their HIV status to 160 their partner (66.3%). Of the 2926 respondents in the study, 2051 (70.1%) received a non-nucleoside reverse 161 transcriptase inhibitor-based regimen, and 874 (21.9%) received a protease inhibitor-based regimen. The 162 duration of antiretroviral therapy (ART) among the respondents ranged from 6 to 204 months, with a median 163 of 101 ± 31 months. Whereas (1743; 59.6%) of the respondents treated with ART have been receiving it for 164 less than 96 months, the remaining 1182 (52.6%) had been on receiving ART for 95 months or more. At the 165 time of the interview, 509 (20.2%) women had opportunistic infections, and 564 (21.9%) had one or more co-166 morbid medical conditions. 167
- 168

Respondents' PHO-9 total score 169

The total score ranged from 0 - 25, with a mean of 5.6 ± 2.3 . Most respondents had PHO-9 scores of less than 170 10 (85.3%), and the remaining respondents (14.7%) had PHQ-9 scores of 10 and above. Only twenty-five 171 172 respondents (0.8%) had a total score of 20 and above.

Sexual dysfunction among the respondents 173

Of the 2926 women with complete questionnaires, 2089 had FSFI score \leq 26.6 or a sexual dysfunction rate of 174 71.4% (CI: 68.4 - 75.3). The distribution of respondents with sexual dysfunction in each of the six domains 175 of sexual function is shown in Table 4. The percentage of sexual dysfunction in the domains ranged from 176 38.8% in the satisfaction domain to 76.8% in the desire domain. At least half of the respondents had 177 dysfunction in desire (76.8%), arousal (66.0%), and orgasm (50.0%) domains. The proportion of respondents 178 with dysfunction in pain. lubrication. and satisfaction domain was 47.2%, 47.2%, and 38.8%, respectively. 179

Risk factors for sexual dysfunction among the cohort 180

- Table 5 shows the relationship between the women's sociodemographic characteristics, co-morbid conditions, 181 HIV characteristics, and sexual dysfunction. On univariate analysis, a significant association was found 182 between women aged 35 years and above (cOR: 1.4; 1.0 - 1.8), marital status (cOR: 0.5; 0.4 - 0.7), PHO Score 183 of 10 and above (cOR: 2.5; 1.6-4.0), postmenopausal state (cOR: 2.5; 1.1-5.6), co-morbid medical condition 184 (cOR: 1.8: 1.1 - 3.0) and SD. No statistically significant association was found between educational status 185 (p=0.51), religion (p=0.47), employment status (p=0.31), and sexual dysfunction. The relationship between 186 HIV-related factors and sexual dysfunction is summarized in Table 6. A statistically significant association 187 was also found between HIV status disclosure (cOR:0.7; 0.6 - 0.97), use of protease inhibitor-based 188 antiretroviral drug regimen (cOR: 1.6; 1.1 - 2.4), duration of antiretroviral therapy of less than 96 months 189 (cOR:1.5; 1.1 - 2.1), the presence of opportunistic infection (cOR: 1.6(1.1 - 2.4)) and sexual dysfunction. Time 190 elapsed since HIV diagnosis (p=0.18), CD4 count (p=0.8), HIV viral load (p=0.1), and partners' positive HIV 191
- 192 status (p=0.6) have no significant association with sexual dysfunction.

After adjustment for potential confounding variables of age, menopausal age, duration of HIV infection, 193 antiretroviral drug regimen, HIV status disclosure, presence of opportunistic infection, PHQ score, and co-194 morbid medical conditions in the multivariate logistic regression model, sexual dysfunction in HIV-positive 195 women had an independent statistically significant association with the postmenopausal state (aOR: 2.0; 1.4 196 197 -4.1), PHQ score of 10 and above (aOR: 2.3; 1.7 - 3.2), co-morbid medical conditions (aOR: 1.8; 1.4 - 2.7), use of protease-based regimen (aOR: 1.3; 1.2 - 2.1), and HIV status disclosure (aOR: 0.7; 0.6-0.8). 198

Discussion 201

Whereas several studies reporting the prevalence and risk factors for sexual dysfunction in the general 202population and select medical conditions abound, ⁴⁰⁻⁴³ data on sexual dysfunction among HIV-positive women 203 is limited.²¹ In Nigeria, with the second largest HIV burden globally, the situation is more dire, as only three 204 publications have reported on sexual dysfunction among HIV-positive women.²³⁻²⁵ The three Nigerian studies 205 were conducted in a predominantly Muslim population with a relatively small sample size, making the findings 206 difficult to generalize. In this study, we determined the prevalence, pattern, and risk factors for sexual 207 dysfunction using information obtained from a large population of HIV-positive women residing in a 208 cosmopolitan city that reflected sociocultural diversity who had been receiving antiretroviral therapy for much 209 longer. The larger sample size also made it possible to conduct subgroup analyses that are powered to make 210 generalization easier. Information obtained in the study will assist in identifying HIV-positive women with 211 sexual dysfunction within the country, within our subregion, and elsewhere to provide adequate care. 212

213

227

The sexual dysfunction rate of 71.4% in this study is within 61.0 - 89.2% reported in Nigerian studies. ²³⁻²⁵ It 214 is, however, higher than the rates reported among HIV-positive women in India⁴⁵ and Europe.^{46,47} Although 215 female sexual dysfunction is a widespread health condition, controversy exists regarding the burden of female 216 sexual dysfunction; vast differences are reported within and between countries. The differences may reflect 217 medical and psychological factors, especially in socioeconomic; cultural; and ethnic differences; the definition 218 used for each type of dysfunction; the type of study tool, the method of data collection; samples; and 219 characteristics of populations studied. ^{23-25, 45-49} In addition, the observed higher prevalence in our setting and 220 sub-Saharan Africa may be due to cultural differences in the settings or reluctance of women in the sub-221 Saharan region to talk openly about sex and seek solutions for their sexual concerns.^{21,23-25, 45-49} The various 222 explanations for the observed differences have also made generalization and comparison of studies 223 challenging. This study used a validated and standardized tool and a specific population group to ensure 224 generalization to our population group and context. This study confirmed that HIV infection is associated with 225 high sexual dysfunction and thus deserves close attention. 23-25, 45-49 226

As expected, the frequency of abnormality in specific sexual function domains is higher in the HIV-positive 228 population studied than in the general population, but it is like the frequency reported in other studies among 229 HIV-positive women. ^{25,45-47,50} Previous studies reported an association between HIV infection and poor 230 quality of life resulting from physical, psychological, or emotional factors. ⁶⁻¹⁰ Medical conditions, including 231 HIV infection, reduce the quality of life and thus impact sexual function.^{20,21} Findings in this study support 232 this assertion, as a co-morbid medical condition (aOR: 1.8; 1.1 - 3.0) and patients' health questionnaire scores 233 of at least 10 (aOR: 2.3; 1.7 - 3.2) retained independent statistically significant association with sexual 234 dysfunction after controlling for potential confounding variables. More than half of the respondents in this 235 study had dysfunction in at least three specific sex domains: desire (76.8%), arousal (66.0%), and orgasm 236 (50.0%). A large proportion also had dysfunction in the remaining three sexual function domains: pain 237 (47.2%), lubrication (47.2%), and satisfaction (38.8%) domain. These findings are similar to previous studies 238 239 conducted in Nigeria and other African countries among HIV-positive women, in which the most prevalent type of sexual dysfunction was in the domain of desire, whereas the least was in the domain of pain.^{21-25,50} 240 The above finding, however, is higher than the findings of studies among the general population, but the 241 distribution of degrees of dysfunction in the various domains was like the findings in women living with 242 HIV.^{30,51-55} Across most studies, dysfunction in the desire domain was the commonest, and dysfunction in the 243 pain domain was the least common, as found in this study. Castelo-Branco et al.,⁵⁴ in their study among healthy 244 women living in Santiago de Chile, found desire disorder (38.0%) the most common, followed by arousal 245 246 disorder (32.0%), pain disorder (33%), and orgasm disorder (25.0%). In a study by Kadri and colleagues⁵⁵ among women living in Morocco, desire disorder was reported by 18%, orgasm disorder by 12%, arousal 247

disorder by 8%, and pain disorder by 8%. The inference that can be made from the above is that while the
severity of specific domain dysfunction may be worse in HIV-positive women, their distribution and pattern
of occurrence are like those in HIV-positive and HIV-negative women.^{21,23-25, 54,55}

The present study found that the postmenopausal state (aOR: 2.5), PHQ score of at least 10 (aOR: 2.5), 251 opportunistic infection (aOR:1.4), co-morbid medical condition (aOR: 1.8), use of protease-based 252 antiretroviral regimen (aOR: 1.3), and HIV status disclosure (aOR: 0.7) were independently associated with 253 sexual dysfunction in women living with HIV infection. A menopausal state was also found as a risk factor 254 for sexual dysfunction in other studies involving women with known HIV status and the general 255 population.^{21,56,57} It is possible that changes in blood hormonal levels with age in women account for their 256 decline in sexual functioning in menopause. ^{21,50,58} These changes occur in all women, not only those HIV-257 positive. The presence of opportunistic infection and co-morbid medical conditions, such as hypertension and 258 diabetes, were also identified as risk factors for sexual dysfunction among women in this study. A common 259 opportunistic infection among the cohort in our clinic is tuberculosis.⁵⁹ Available literature has reported that 260 active tuberculosis disrupts sexual function in male and female patients. Tuberculosis usually disturbs 261 the mental and physical well-being of those infected. Its chronic nature, long isolation period, and 262 enormous pill burden taken over a long period may lead to sexual dysfunction. Tuberculosis of the female 263 genital tract is one of the leading causes of reproductive dysfunction as well.⁶⁰ Sexual dysfunction is 264 frequently a challenge in patients with other medical diseases, such as hypertension and diabetes, and it may 265 occur either as a side effect of medications or as a component of the dysmetabolic syndrome of high blood 266 pressure. ^{30,33} Hypertension and diabetes are two common medical comorbidities in our environment 267 among the HIV patient population,⁶¹ and 61.0 - 88% of patients with these diseases have sexual 268 dysfunction;^{21,25,33,62} thus, it is not surprising that co-morbid conditions retained an independent 269 statistical association with sexual dysfunction even after controlling for other possible confounders. This 270association was also found in other studies in our environment. ^{21,30,33} The use of antiretroviral therapy 271 272 has been shown to ameliorate sexual dysfunction in several studies²¹; however, we could not access this variable in our study, as it is now unethical not to start HIV-positive patients on antiretroviral therapy; 273 274 the studies that reported the association between sexual dysfunction and the use of antiretroviral therapy were conducted before the treat-all policy was instituted. In the present study, we could only assess if 275 there is an association between the type of antiretroviral therapy regimen and sexual dysfunction; this 276 study, like some other previous studies,^{63,64} found that the use of protease inhibitors was an independent 277 risk factor for sexual dysfunction in HIV- positive women. Schrooten et al., 63, in their study in 10 European 278 279 countries of HIV-positive patients receiving antiretroviral agents, found a decrease in sexual interest and potency among those receiving protease inhibitors compared with protease inhibitor-naive patients. 280

In this study, non-disclosure of HIV status was also an independent risk factor for sexual dysfunction. This 281 finding is consistent with the findings of previous studies.^{21,23} In women with HIV, sexual dysfunction is 282 complex because of contextual sociocultural issues, financial challenges, depression, caregiving duties, and 283 challenges of status disclosure.^{21-23,50,65} These issues are most likely to affect sexual function. However, the 284 most challenging is the fear of disclosure of HIV status (which is known to result in violence) and the 285 associated guilt, especially if the partner is HIV-negative or of unknown status. It is, therefore, not surprising 286 that non-disclosure was found to be a risk factor for sexual dysfunction. The guilt of infecting an HIV-negative 287 288 partner or the fear of violence following disclosure has the potential to impact the sexual functioning of the women involved negatively. 289

290

292 **Strengths and limitations**

Our study has strengths: It was conducted in an HIV-endemic country with a large sample size using an 293 internationally accepted and validated tool. The study was also conducted in a cosmopolitan city with 294 sociocultural, religious, and economic diversity mimicking what is present nationally. However, the study also 295 has limitations: its cross-sectional design did not allow for the assessment of the temporal association between 296 sexual dysfunction and various factors studied. The study was conducted in a single city and clinic, though of 297 more than 20 million population and over 20,000 patients; this makes it difficult to generalize to all women 298 living with HIV in Nigeria. FSFI, the study tool, has been criticized for considering only penetrative sex as 299 the single requirement for sexual well-being. Finally, about 10% of eligible patients who were approached 300 declined to participate, failed to return the data collection form, or returned incompletely answered forms: 301 although the rate was relatively low, it could still have affected the generalizability of the study results. 302

303 Conclusions

Sexual dysfunction is a significant public health challenge among HIV-positive women in Nigeria and sub-304 Saharan Africa, where HIV is endemic. The sexual dysfunction rate of 71.4% confirms that it is a significant 305 challenge in our setting. Sexual dysfunction in the six domains ranged from 38.8% in the satisfaction domain 306 to 76.8% in the desire domain. Six factors are significantly associated with sexual dysfunction; menopausal 307 state, PHO score of 10 and above, opportunistic infection, co-morbid medical condition, use of protease-based 308 antiretroviral regimen, and non-disclosure of HIV status. There is a need to sensitize and train healthcare 309 workers to assess for sexual challenges during routine programmatic consultations. The national HIV 310 programs should, as a matter of urgency, include screening and treatment of sexual dysfunctions among HIV-311 positive women in the country's treatment guidelines. 312

313 References

- 1. McGee C. The Continuing Impact of HIV/AIDS on Development in Africa: A Systematic Analysis Using 314 the Political Systems and Contagious Disease Theories. InAfrica and Globalization 2020 (pp. 171-187). 315 Palgrave Macmillan, Cham. 316
- Giguère K, Eaton JW, Marsh K, Johnson LF, Johnson CC, Ehui E, Jahn A, Wanyeki I, Mbofana F, 2. 317 Bakiono F, Mahy M. Trends in knowledge of HIV status and efficiency of HIV testing services in sub-318 Saharan Africa, 2000-20: a modelling study using survey and HIV testing programme data. The Lancet 319 320 HIV. 2021 May 1;8(5):e284-93.
- Ukaegbu E, Alibekova R, Ali S, Crape B, Issanov A. Trends of HIV/AIDS knowledge and attitudes among 3. 321 Nigerian women between 2007 and 2017 using Multiple Indicator Cluster Survey data. BMC Public 322 323 Health. 2022 Dec;22(1):1-2.
- Mojola SA, Angotti N, Denardo D, Schatz E, Xavier Gómez Olivé F. The end of AIDS? HIV and the new 324 325 landscape of illness in rural South Africa. Global Public Health. 2022 Jan 2;17(1):13-25.
- Rintamaki L, Kosenko K, Hogan T, Scott AM, Dobmeier C, Tingue E, Peek D. The role of stigma 326 5. management in HIV treatment adherence. International journal of environmental research and public 327 health. 2019 Dec;16(24):5003. 328
- 6. Alexander G, Thomas RA. Health-Related Quality of Life in HIV-positive Women on Long-Term 329 Antiretroviral Therapy-A Study from Bangalore, South India. World Journal of AIDS. 2022 Apr 330 11;12(2):97-110. 331
- 332 7. Rasoolinajad M, Abedinia N, Noorbala AA, Mohraz M, Badie BM, Hamad A, Sahebi L. Relationship among HIV-related stigma, mental health and quality of life for HIV-positive patients in Tehran. AIDS 333 and Behavior. 2018 Dec;22(12):3773-82. 334
- 335 Karugaba G, Thupayagale-Tshweneagae G, Moleki MM, Mabikwa OV, Matshaba M. Determinants of 8. health-related quality of life in young adults living with perinatally acquired HIV infection in Botswana. 336 Southern African Journal of HIV Medicine. 2022 Apr 29;23(1):10. 337
- 9. Abebe Weldsilase Y, Likka MH, Wakayo T, Gerbaba M. Health-related quality of life and associated 338 factors among women on antiretroviral therapy in health facilities of Jimma Town, Southwest Ethiopia. 339 Advances in Public Health. 2018 Sep 16:2018. 340
- 10. Osei-Yeboah J, Owiredu WK, Norgbe GK, Lokpo SY, Obirikorang C, Alote Allotey E, Gameli Deku J, 341 Akomanin Asiamah E, Manaphraim NY, Senyo Kwasi Nyamadi P, Yiadom Boakye E. Quality of life of 342 people living with HIV/AIDS in the Ho Municipality, Ghana: a cross-sectional study. AIDS research and 343 treatment. 2017 Oct 24;2017. 344
- 345 11. Alemayehu M, Wubshet M, Mesfin N, Tamiru A, Gebayehu A. Health-related quality of life of HIV infected adults with and without Visceral Leishmaniasis in Northwest Ethiopia. Health and quality of life 346 outcomes. 2017 Dec;15(1):1-0. 347
- 348 12. Surur AS, Teni FS, Wale W, Avalew Y, Tesfave B. Health related quality of life of HIV/AIDS patients on highly active antiretroviral therapy at a university referral hospital in Ethiopia. BMC health services 349 research. 2017 Dec;17(1):1-8. 350
- 13. Sineke T, Evans D, Schnippel K, van Aswegen H, Berhanu R, Musakwa N, Lönnmark E, Long L, Rosen 351 S. The impact of adverse events on health-related quality of life among patients receiving treatment for 352 drug-resistant tuberculosis in Johannesburg, South Africa. Health and quality of life outcomes. 2019 353 354 Dec;17(1):1-5.
- 14. Kimera E, Vindevogel S, De Maeyer J, Reynaert D, Engelen AM, Nuwaha F, Rubaihayo J, Bilsen J. 355 Challenges and support for quality of life of youths living with HIV/AIDS in schools and larger community 356
- in East Africa: a systematic review. Systematic Reviews. 2019 Dec;8(1):1-8. 357

- 15. Oladeji BD, Taiwo B, Mosuro O, Fayemiwo SA, Abiona T, Fought AJ, Robertson K, Ogunniyi A,
 Adewole IF. Suicidal behavior and associations with quality of life among HIV-infected patients in Ibadan,
 Nigeria. Journal of the International Association of Providers of AIDS Care (JIAPAC). 2017
 Jul;16(4):376-82.
- 16. Kanu NE, Tobin-West CI. Health-related quality of life of HIV patients with and without tuberculosis
 registered in a Tertiary Hospital in Port Harcourt, Nigeria. HIV & AIDS Review. International Journal of
 HIV-Related Problems. 2018 Jan 1;17(3):210-7.
- 17. Biambo AA, Adibe MO, Liman HM, Ukwe CV. Health-related quality of life of HIV-infected patients
 taking different antiretroviral regimens at a tertiary healthcare facility in northern Nigeria. Tropical Journal
 of Pharmaceutical Research. 2018 May 11;17(3):549-57.
- 18. Suleiman BA, Yahaya M, Olaniyan FA, Sule AG, Sufiyan MB. Determinants of health-related quality of
 life among human immunodeficiency virus positive (HIV-positive) patients at Ahmadu Bello University
 teaching hospital, Zaria, Nigeria-2015. BMC Public Health. 2020 Dec;20(1):1-9.
- 19. Onyekonwu CL, Onyeka TC, Brenda NC, Ijoma UN, Unaogu NN, Onwuekwe IO, Ugwumba F, Nwutobo
 CR, Nwachukwu CV. Chronic HIV infection and health related quality of life in resource poor settingsan assessment from South East Nigeria. African Health Sciences. 2020 Apr 20;20(1):102-13.
- 20. Mehta SD, Nordgren RK, Agingu W, Otieno F, Odongo W, Odhiambo F, Bailey RC. Sexual quality of
 life and association with HIV and sexually transmitted infections among a cohort of heterosexual couples
 in Kenya. The journal of sexual medicine. 2018 Oct 1;15(10):1446-55.
- 21. Huntingdon B, Muscat DM, de Wit J, Duracinsky M, Juraskova I. Factors associated with general sexual
 functioning and sexual satisfaction among people living with HIV: a systematic review. The Journal of
 Sex Research. 2020 Sep 1;57(7):824-35.
- 22. Bouhlel S, Derbel CH, Nakhli J, Bellazreg F, Meriem HB, Omezzine A, Ali BB. Sexual dysfunction in
 Tunisian patients living with HIV. Sexologies. 2017 Apr 1;26(2):e11-6.
- 23. Agaba PA, Meloni ST, Sule HM, Agaba EI, Idoko JA, Kanki PJ. Sexual dysfunction and its determinants
 among women infected with HIV. International Journal of Gynecology & Obstetrics. 2017
 Jun;137(3):301-8.
- 24. Abiodun O, Sodeinde K, Adepoju A, Ohiaogu F, Mbonu F, Adelowo O, Bankole O. Sexual functioning,
 sexual distress, and well-being of sexually active adult women living with HIV: an HIV program-based
 cross-sectional study. Sexuality Research and Social Policy. 2020 Dec;17(4):558-67.
- 25. Oyedokun, A., Odeigah, L., Alabi, K., Adegunloye, O., Akujobi, H. (2014) Sexual dysfunction in HIV positive women attending a tertiary health facility in North Central Nigeria. J AIDS Clin Res, 5: 398-398
- 26. Wilson TE, Jean-Louis G, Schwartz R, Golub ET, Cohen MH, Maki P, Greenblatt R, Massad LS, Robison
 E, Goparaju L, Lindau S. HIV infection and women's sexual functioning. J Acquir Immune Defic Syndr.
 2010 Aug;54(4):360-7. doi: 10.1097/QAI.0b013e3181d01b14. PMID:
- 27. Shindel AW, Horberg MA, Smith JF, Breyer BN. Sexual dysfunction, HIV, and AIDS in men who have
 sex with men. AIDS Patient Care STDS. 2011 Jun;25(6):341-9. doi: 10.1089/apc.2011.0059. Epub 2011
 Apr 18. PMID: 21501095; PMCID: PMC3101920.
- 28. Russell DB. Sexual function and dysfunction in older HIV-positive individuals. Sex Health. 2011
 Dec;8(4):502-7. doi: 10.1071/SH11041. PMID: 22127035.
- 29. Scanavino Mde T. Sexual Dysfunctions of HIV-Positive Men: Associated Factors, Pathophysiology
 Issues, and Clinical Management. Adv Urol. 2011;2011:854792. doi: 10.1155/2011/854792. Epub 2011
 Oct 20. PMID: 22046183; PMCID: PMC3199204.
- 30. Collazos J, Martínez E, Mayo J, Ibarra S. Sexual dysfunction in HIV-infected patients treated with highly
 active antiretroviral therapy. J Acquir Immune Defic Syndr. 2002 Nov 1;31(3):322-6. doi:
 10.1097/00126334-200211010-00008. PMID: 12439208.

- 404 31. De Vincentis S, Tartaro G, Rochira V, Santi D. HIV and Sexual Dysfunction in Men. J Clin Med. 2021
 405 Mar 5;10(5):1088. doi: 10.3390/jcm10051088. PMID: 33807833; PMCID: PMC7961513.
- 406 32. Fajewonyomi BA, Orji EO, Adeyemo AO. Sexual dysfunction among female patients of reproductive age
 407 in a hospital setting in Nigeria. Journal of Health, Population and Nutrition. 2007 Mar 1:101-6.
- 33. Shaeer KZ, Osegbe DN, Siddiqui SH, Razzaque A, Glasser DB, Jaguste V. Prevalence of erectile
 dysfunction and its correlates among men attending primary care clinics in three countries: Pakistan,
 Egypt, and Nigeria. International journal of impotence research. 2003 Apr 1;15:S8-14.
- 34. Okeahialam BN, Obeka NC. Sexual dysfunction in female hypertensives. Journal of the National Medical
 Association. 2006 Apr;98(4):638.
- 35. Audu BM. Sexual dysfunction among infertile Nigerian women. Journal of Obstetrics and Gynaecology.
 2002 Jan 1;22(6):655-7.
- 36. Orji EO, Ogunlola IO, Fasubaa OB. Sexuality among pregnant women in South West Nigeria. J Obstet
 Gynaecol. 2002;22:166-8.
- 37. Adeniyi FA, Adeleye OJ, Adeniyi YC. Diabetes, sexual dysfunction and therapeutic exercise: a 20 year
 review. Current diabetes reviews. 2010 Jul 1;6(4):201-6.
- 419 38. Raosoft Incorporated. Raosoft Sample size calculator 2004. Available from
- 420 URL:<u>http://www.raosoft.com/samplesize.html</u>.
- 39. Kroenke, K., Spitzer, R.L., Williams, J.B., 2001. The PHQ-9. Validity of a brief depression severity
 measure. J. Gen. Intern. Med. 16, 606–613.
- 40. Adewuya AO, Ola BA, Afolabi OO. Validity of the Patient Health Questionnaire (PHQ-9) as a screening
 tool for depression amongst Nigerian university students. Journal of Affective Disorders 2006; 96: 9–93
- 41. Rosen, C. Brown, J. Heiman, S. Leiblum, C. Meston, R. Shabsigh, D. Ferguson, R. D'Agostino R. The
 Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of
 female sexual function. Journal of Sex & Marital Therapy. 2000;26(2):191-208.
- 428 42. Wiegel M, Meston C, Rosen R. The female sexual function index (FSFI): cross-validation and
 429 development of clinical cut-off scores. J Sex Marital Ther. 2005 Jan-Feb;31(1):1-20. doi:
 430 10.1080/00926230590475206. PMID: 15841702.
- 43. Nwagha UI, Oguanuo TC, Ekwuazi K, Olubobokun TO, Nwagha TU, Onyebuchi AK, Ezeonu PO,
 Nwadike K. Prevalence of sexual dysfunction among females in a university community in Enugu,
 Nigeria. Nigerian journal of clinical practice. 2014;17(6):791-6.
- 434 44. Meston CM. Validation of the Female Sexual Function Index (FSFI) in women with female orgasmic
 435 disorder and in women with hypoactive sexual desire disorder. J Sex Marital Ther. 2003 Jan436 Feb;29(1):39-46. doi: 10.1080/713847100. PMID: 12519665; PMCID: PMC2872178.
- 437 45. Muthiah B, Kallikadavil A, Shivaswamy R, Menon VB. The Study of Gonadal Hormonal Abnormalities
 438 and Sexual Dysfunction in HIV Positive Females: An Exploratory Study. Journal of Clinical and
 439 Diagnostic Research : JCDR. 2016;10(4):OC11-OC14. doi:10.7860/JCDR/2016/18992.7581.
- 440 46. Goggin K, Engelson ES, Rabkin JG, Kotler DP. The relationship of mood, endocrine, and sexual disorders
 441 in human immunodeficiency virus positive (HIV+) women: an exploratory study. Psychosom Med 1998,
 442 60:11-16
- 47. Florence E, Schrooten W, Dreezen C, Gordillo V, Schönnesson LN, Asboe D, Koitz G, Colebunders R,
 Eurosupport Study Group T. Prevalence and factors associated with sexual dysfunction among HIVpositive women in Europe. AIDS care. 2004 Jul 1;16(5):550-7.

- 48. Mezones-Holguin E, Cordova-Marcelo W, Lau-Chu-Fon F, Aguilar-Silva C, Morales-Cabrera J, 446 447 Bolanos-Diaz R, et al. Association between sexual function and depression in sexually active, mid-aged, Peruvian women. Climacteric 2011;14:654-60. 448
- 49. Safarinejad MR. Female sexual dysfunction in a population-based study in Iran: prevalence and associated 449 risk factors. International Journal of Impotence Research. 2006 Jul 1;18(4):382-95. 450
- 50. Camara A, Tounkara TM, Delamou A, Baldé R, Leno NN, Kuotu GC, Touré A, Cissé M. Prevalence 451 and risk factors of female sexual dysfunction among women infected with HIV in conakry. Clinical 452 Epidemiology and Global Health. 2021 Oct 1;12:100828. 453
- 51. Turan V, Kopuz A, Ozcan A, Kocakaya B, Sahin C, Solmaz U. Sexual dysfunction in infertile Turkish 454 females: prevalence and risk factors. European Journal of Obstetrics & Gynecology and Reproductive 455 Biology. 2014;30;182:128-31. 456
- 52. Aygin D & Eti Aslan F (2008) A study of sexual dysfunction in women with breast cancer. The Journal 457 of Breast Health 4, 105-114. 458
- 459 53. Cayan S, Akbay E, Bozlu M, Canpolat B, Acar D, Ulusoy E. The prevalence of female sexual dysfunction and potential risk factors that may impair sexual function in Turkish women. Urologia Internationalis 460 2004;72, 52-57. 461
- 54. Castelo-Branco C, Blumel JE, Arava H, Riquelme R, Castro G, Hava J et al. Prevalence of sexual 462 dysfunction in a cohort of middle-aged women: influences of menopause and hormone replacement 463 therapy. J Obstet Gynaecol 2003; 23: 426-430. 464
- 55. Kadri N. Mchichi Alami KH, Mchakra Tahiri S. Women sexual dysfunction: a population-based 465 epidemiological study. Arch Women Ment Health 2002; 5: 59-63. 466
- 56. Ishak IH, Low WY, Othman S. Prevalence, risk factors, and predictors of female sexual dysfunction in a 467 primary care setting: a survey finding. The journal of sexual medicine. 2010 Sep 1;7(9):3080-7. 468
- 57. Hassanin IM, Helmy YA, Fathalla MM, Shahin AY. Prevalence and characteristics of female sexual 469 dysfunction in a sample of women from Upper Egypt. International Journal of Gynecology & Obstetrics. 470 2010 Mar 1;108(3):219-23. 471
- 58. Bernhard LA. Sexuality and sexual health care for women. Clinical Obstetrics and gynecology. 2002 472 Dec 1;45(4):1089-98. 473
- 59. Onwujekwe DI, Ezechi OC, Ezeobi PM, Gbajabiamila TA. Incidence And Pattern Of Tuberculosis In HIV 474 Infected Adult In Lagos Nigeria. NJCBR Online. 2017;7(9):23-8. 475
- 60. Kulchavenya E, Khomyakov V. Tuberculosis as a reason for male and female sexual dysfunction. Version: 476 2018-10-04. In: Bjerklund Johansen TE, Wagenlehner FME, Matsumoto T, Cho YH, Krieger JN, Shoskes 477 478 D, Naber KG, editors. Urogenital Infections and Inflammations. Berlin: German Medical Science GMS Publishing 2017-. 479 House:
- DOI: 10.5680/lhuii000041 480
- 61. Iwelunmor J, Ezechi O, Obiezu-Umeh C, Gbajabiamila T, Musa AZ, Oladele D, Idigbe I, Ohihoin A, 481 482 Gyamfi J, Aifah A, Salako B. Capabilities, opportunities and motivations for integrating evidence-based strategy for hypertension control into HIV clinics in Southwest Nigeria. PloS one. 2019 Jun 483 484 6;14(6):e0217703.
- 62. Ogbera AO, Chinenye S, Akinlade A, Eregie A, Awobusuyi J. Frequency and correlates of sexual 485
- dysfunction in women with diabetes mellitus. The journal of sexual medicine. 2009 Dec 1;6(12):3401-6. 486
- 63. Schrooten W. Colebunders R. Youle M. Molenberghs G. Dedes N. Koitz G. Finazzi R. de Mey I. Florence 487
- E, Dreezen C, Eurosupport Study Group. Sexual dysfunction associated with protease inhibitor containing 488
- 489 highly active antiretroviral treatment, AIDS: May 25, 2001 - Volume 15 - Issue 8 - p 1019-1023

- 64. Martinez E, Collazos J, Mayo J. Sexual dysfunction with protease inhibitors. Lancet 1999, 353: 810 -490 491 811.
- 492 65. Goldmeier D, Kocsis A, Wasserman M. Sexual dysfunction in women with HIV. Sexually Transmitted
- 493 Infections. 2005 Aug 1;81(4):284-.
- 494

Table 1. Sociodemographic characteristics of 2926 HIV-positive women in the study

Characteristics	No. of Respondents (%)			
Age (Years)				
• < 35	2007(68.6)			
• \geq 35	919(31.4)			
Nigerian ethic Groups				
• Major ethnic groups (Igbo, H/Fulani, and	2218(75.8)			
Yoruba)				
Ethnic minorities	708(24.2)			
Education				
• < Secondary	629(21.5)			
• \geq Secondary	2296(78.5)			
Employment status				
Working	1741(59.5)			
Not working	1185(40.5)			
Marital status				
Married	1553(53.1)			
Not married	1372(46.9)			
Religion				
Christianity	2142(73.2)			
• Islam	711(24.9)			
• Others	73(2.5)			
Menopausal state				
• Premenopausal	2494(85.2)			
Postmenopausal	432(14.8)			

Table 2. HIV-related characteristics of the 2926 respondents in the study

Characteristics	Frequency (%)		
Time since HIV diagnosis (months)			
• <120	1653(56.5)		
• ≥ 120	1273(43.5)		
CD4 counts (2867)			
• <200	757(26.4)		
• ≥ 200	2110(73.6)		
• Median (SD)	563 (194)		
Viral load (2519)			
• Not detected	1569(62.3)		
• Detected	950(37.7)		
Partner HIV status (2448)			
Negative	1065(43.5)		
Positive	1383(56.5)		
HIV status Disclosure (2725)			
• Disclosed	1807(66.3)		
Not disclosed	918(33.4)		
Type of antiretroviral therapy regimen			
NNRTI based	2051(70.1)		
• PI based	874(29.9)		
Duration on ART (months)			
• < 96	1743(59.6)		
 ≥96 	1182(40.4)		
• Median (SD)	101(31)		
Opportunistic infection (2525)			
• Yes	509(20.2)		
• No	2016(79.8)		
Co-morbid medical condition (2575)			
• Yes	564(21.9)		
• No	2011(78.1)		
• No	2011(70.1)		

Total score	Number of Respondents (%)
5-9	2495(85.3)
10 – 14	313(10.7)
15 – 19	93(3.2)
≥ 20	25(0.8)
Range	0-25
Mean (SD)	5.6 (2.3)

Table 4. Distribution of domain-specific sexual dysfunction among the 2926 respondents in the study 504

Sexual Domains	Number of respondents with sexual
	dysfunction (%)
Desire	2247 (76.8)
Arousal	1931 (66.0)
Lubrication	1381 (47.2)
Orgasm	1463 (50.0)
Satisfaction	1135 (38.8)
Pain	1381 (47.2)

Table 5. Relationship between sociodemographic variables and sexual dysfunction among 2926 HIV-positive women in the studyTable 6. Relationship between HIV-related variables and sexual dysfunction among 2926 HIV-positive women in the study

Variables	Sexual dysfunction	Normal sexual function	Crude Odds	P value	Adjusted Odds	P value
	N= 2089	N=837	Ratio (95% CI)		Ratio (95% CI)	
Age(years)						
• <35	1393(69.4)	614(30.6)	1.0		1.0	
• ≥35	696(75.7)	223(24.3.)	1.4(1.0 - 1.8)	0.04	1.1(0.8-1.5)	0.09
Education						
• < Secondary	447(71.1)	182(28.9)	0.9(0.7-1.14	0.51	-	-
• \geq Secondary	1642(71.4)	655(28.6)	1.0		-	
Employment status						
Working	1253(72.0)	488(28.0)	1.1(0.8-1.4)	0.31	-	-
• Not working	836(70.5)	349(29.5)	1.0		-	
Marital status						
Married	1062(68.4)	491(31.6)	0.5(0.4-0.7)	0.00	0.9(0.6-1.1)	0.05
• Not married	1027(74.8)	346(25.2)	1.0		1.0	
Religion						
• Christianity	1525(71.2)	617(28.8)	1.0(0.7-1.3)	0.47	-	-
• Islam	504(70.9)	207(29.1)	1.0		-	
PHQ Score						
• <10	1723(69.1)	772(30.9)	1.0		1.0	
 ≥10 	366(84.9)	65(15.1)	2.5(1.6 - 4.0)	0.000	2.3(1.7 - 3.2)	0.000
Postmenopausal status	370(85.7)	62(14.3)	2.5(1.1 - 5.6)	0.013	2.0(1.4-4.1)	0.02
Co-morbid medical disorders	456(80.8)	108(19.2)	1.8(1.1 - 3.0)	0.02	1.8(1.4-2.7)	0.001
HIV Variables	Sexual dysfunction N=2089	Normal sexual function	Crude OR	P value	Adjusted OR	P value
	N=2089	N=837	(95% CI)		(95% CI)	
Time since HIV diagnosis (months)	11(0(70.0)			0.10		
• < 120	1160(70.2)	493(29.8)	0.9(0.7-1.1)	0.18	-	-

• ≥120	929(72.9)	344(27.1)	1.0		-	
CD4 count						
• <200	560(74.0)	197(26.0)	1.8(0.6 - 3.1)	0.81	-	-
• ≥ 200	1529(72.5)	581(27.5)	1.0		-	
Viral load						
• Not detected	1092(69.6)	477(30.4)	0.8(0.6 - 1.0)	0.1	-	-
• Detected	590(62.1)	360(37.9)	1.0		-	
Partner HIV status						
Positive	1001(72.4)	383(27.6)	1.1(0.8 - 1.5)	0.60	-	-
Negative	753(70.7)	312(29.4)	1.0		-	
HIV status disclosure						
Disclosed	1250(69.2)	557(30.8)	0.7(0.6 - 0.97)	0.04	0.7(0.6-0.8)	0.03
Not disclosed	692(75.4)	226(24.2)	1.0		1.0	
Antiretroviral drug regimen						
NNRTI based	135866.2)	693(33.9)	1.0	0.01	1.0	0.01
PI Based	664(76.0)	210(24.0)	1.6(1.1 - 2.4)		1.3(1.2 - 2.1)	
Duration on HAART (month)				0.00		0.06
• < 96	1333(76.5)	410(23.5)	1.5(1.1-2.1)		1.4(0.9-2.4)	
• ≥96	801(67.8)	381(32.2)	1.0	0.01	1.0	0.07
Had opportunistic infection	401(78.8)	108(21.2)	1.6(1.1 – 2.4)		1.4(0.8-1.7)	

NNRTI: Nucleoside reverse transcriptase inhibitors; PI: Protease inhibitor